We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Contingency plan

6 July 2016 By Robert Cyran

The French pharmaceuticals group is dangling a so-called contingent value right in its richer $11 bln offer for Medivation. A similar special payout predicated on a drug’s success helped Sanofi seal a deal for Genzyme in 2011. The result there should give the latest target pause.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)